On Wednesday, Shares of Wells Fargo & Company (NYSE:WFC), gained 0.93% to $57.78.
Wells Fargo & Company, stated net income of $5.7 billion, or $1.03 per diluted common share, for second quarter 2015, contrast with $5.7 billion, or $1.01 per share, for second quarter 2014, and $5.8 billion, or $1.04 per share, for first quarter 2015.
Net interest income raised $284 million from first quarter 2015 to $11.3 billion, primarily due to broad-based asset growth counting investment securities, loans, trading assets and mortgages held-for-sale. The quarter also comprised of one additional day, accounting for about 25 percent of the enhance in net interest income relative to the first quarter. Net interest income also benefited from raised income from variable sources, lower deposit costs, and higher income from interest rate swaps used to convert a portion of their floating rate commercial loans to fixed rate as the company continued to add duration to our balance sheet.
Net interest margin was 2.97 percent, up 2 basis points from first quarter 2015. Many of the same factors that improved net interest income this quarter, counting growth in investments and loans, and lower deposit costs, combined to improve the net interest margin by about 4 basis points linked-quarter, and income from variable sources contributed 1 basis point. These benefits were partially offset by growth in customer deposits, which had a minimal impact to net interest income, but was dilutive to net interest margin by 3 basis points.
Wells Fargo & Company provides retail, commercial, and corporate banking services to individuals, businesses, and institutions. Its Community Banking segment offers checking, savings, market rate, individual retirement, and health savings accounts, in addition to time deposits and remittances; and lines of credit, auto floor plan lines, equity lines and loans, equipment and transportation loans, education and residential mortgage loans, and debit and credit cards.
Shares of Texas Instruments Inc. (NASDAQ:TXN), declined -0.54% to $49.49, during its last trading session.
Bluvision , and Texas Instruments Incorporated, declared the availability of Bluvision IoT sensor beacons with support for Eddystone, an open beacon format from Google, Apple’s iBeacon™ technology and an array of onboard sensor data enabling true Internet of Things (IoT) deployments and delivering relevant proximity based mobile content to consumers.
With full support for Eddystone and iBeacon standards, Bluvision’s IoT sensors leverage TI’s SimpleLink Bluetooth® Smart CC2640 wireless microcontroller which gives Bluvision beacons the longest battery life, flexibility to support all major protocols and the ability to connect to multiple sensors.
As the first beacon technology company to fully support all beacon protocols (iBeacon and Eddystone) Bluvision uses CC2640 to connect beacons and sensors to each other and to the cloud in IoT applications such as indoor navigation, micro-location-based services, asset tracking, inventory administration, analytics and beyond, driving IoT into the mainstream.
Texas Instruments Incorporated designs, manufactures, and sells semiconductors to electronics designers and manufacturers worldwide. It operates through two segments, Analog and Embedded Processing. The Analog segment offers high volume analog and logic products for automotive safety devices, touch screen controllers, low voltage motor drivers, and integrated motor controllers; and power administration products to enhance the efficiency of powered devices using battery administration solutions, portable power conversion devices, power supply controls, and point-of-load products.
Finally, Illumina Inc. (NASDAQ:ILMN), ended its last trade with -0.08% loss, and closed at $229.08, hitting its highest level.
Illumina, Inc., declared that a preliminary study retrospectively correlated 10 cases of occult maternal cancer among pregnant women receiving an “aneuploidy detected” or “aneuploidy suspected” positive results on the verifi® noninvasive Prenatal Test (NIPT)1 to discordant results of fetal karyotypes for the women, suggesting that discordant NIPT test results may be indicative of maternal cancer.
Maternal cancers sometimes leave tell-tale abnormal cell free DNA fragments in plasma. In 8 of 10 stated cancer cases, Illumina scientists and physicians reviewed all the genome-wide sequencing data and identified nonspecific copy-number changes across multiple chromosomes, suggesting that these changes, when present in a woman whose fetal karyotype tests as normal, might represent a signal to the clinician to probe for the presence of cancer.
The results of the study, entitled “Noninvasive Prenatal Testing and Incidental Detection of Occult Malignancies,” are accessible online recently in The Journal of the American Medical Association and the full article can be accessed at broadcast.jamanetwork.com. The paper will be comprised of in the July 14 print edition of JAMA.
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
